Breaking News

Catalent Expands OptiMelt Capabilities at Somerset CoE

Investing an additional $5 million in manufacturing and analytical equipment to enhance development capabilities to support HME formulations

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent Pharma Solutions is investing an additional $5 million at the company’s Somerset, NJ, drug development center of excellence to expand its OptiMelt hot melt extrusion (HME) capabilities.   HME is used in the development of amorphous dispersions and controlled and modified drug delivery to enhance a drug’s bioavailability, as well as taste masking of bitter active pharmaceutical ingredients (APIs). The investment will include the addition of a number of pieces of manufacturing and analy...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters